Business
DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS ...
About this update from Devonian Health Group, Inc.
[{"type":"text","content":"\n\n\nDEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\nCanada NewsWire\n\n\nQUÉBEC, Feb. 2, 2026 /CNW/ - Devonian Health Group Inc. (\"Devonian\" or the \"Company\") (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, is pleased to announce that it has appointed Dennis Turpin as Chief Financial Officer of the Company, effective today. Mr. Turpin currently serves and will remain on the Board of Directors of the Company. Before his appointment as Chief Financial Officer, he also served as Chair of the Audit Committee, a role that will now be assumed by Mr. Pierre Labbé.\n\n\n\n\n\n\n\nMr. Turpin is a seasoned professional executive and chartered professional accountant (CPA) with significant experience in finance, capital markets transactions, business development as well as mergers and acquisitions, over 25 years of which have been in the biopharmaceutical industry.\n\"I am pleased to welcome Dennis and confident that he will help strengthen our management approach, diversify our perspectives, enhance our collective expertise, and help guide the development of Devonian.\" said Dr. André P. Boulet, PhD, Chief Executive Officer. \nMr. Turpin will replace Viktoria Krasteva, who will remain with the Company and assist ensuring a smooth transition until February 27, 2026. The Board would like to thank Ms. Krasteva for her contributions to the Company and wishes her well in her future endeavors.\nA total of 25,000 stock options were granted to Mr. Turpin.  These options are vesting immediately and are exercisable at a price of $11.50, for a period of 10 years following the grant date.\nOptions Grant Updates\nThe Company also wishes to correct the press release issued on December 19, 2025, regarding the granting of 2,948,056 stock options to directors and a consultant of the Company, as well as the additional grants of 385,950 stock options to employees and 100,000 stock options to ...